Prompt use of medications may slow BPH progression.
Early use of drugs known as 5-alpha reductase inhibitors (5-ARIs) may reduce the risk of clinical progression in men taking an alpha-blocker medication for benign prostatic hyperplasia (BPH, or enlarged prostate), suggests a study in the August issue of Pharmacy & Therapeutics. The 5-ARIs include finasteride (Proscar) and dutasteride (Avodart), while alpha-blockers include alfuzosin (Uroxatral), tamsulosin (Flomax), and si.lodosin (Rapaflo). Researchers analyzed data on 8,617 men with BPH, dividing them into those who began 5-ARI therapy early (within 30 days of starting an alpha-blocker) and those on a delayed regimen (30-180 days after starting an alpha-blocker). They assessed the likeli-hood that the men's BPH would progress to acute urinary retention (a sudden inability to urinate) or necessitate surgery over a one-year period. Compared to men receiving delayed 5-AKI therapy, those given early treatment were nearly 5 percent less likely to experience clinical progression of their BPH, 3.6 percent less likely to develop acute urinary retention, and 2 percent less likely to require surgery, the study found. The take-home message: If you have BPH, ask your doctor about adding a 5-ARI to alpha-blocker therapy to reduce your risk of progression.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||NEWS BRIEFS|
|Publication:||Men's Health Advisor|
|Article Type:||Brief article|
|Date:||Dec 1, 2011|
|Previous Article:||Combo of lifestyle factors greatly trims diabetes risk.|
|Next Article:||High-normal blood pressure increases stroke risk.|